Evidence map›Paper›PMID 33603081›Full record

ArticleScientific reports2021

Decongestant use and the risk of myocardial infarction and stroke: a case-crossover study.

Lamiae Grimaldi-Bensouda, Bernard Begaud, Jacques Benichou, Clementine Nordon, Olivia Dialla, Nicolas Morisot, Yann Hamon, Yves Cottin, Elie Serrano, Lucien Abenhaim and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Lamiae Grimaldi-BensoudaThe PGRx Study Group, Paris, France. Lamiae.Grimaldi@aphp.fr.
Bernard BegaudDépartement de Pharmacologie Médicale, Equipe "Pharmaco-Epidémiologie et Impact des Médicaments sur Les Populations", Bordeaux Population Health Research Center INSERM U1219, Bordeaux, France.
Jacques BenichouHôpital Universitaire de Rouen, Rouen, France.
Clementine NordonThe PGRx Study Group, Paris, France.
Olivia DiallaLaser Core Paris, Paris, France.
Nicolas MorisotLaser Core Paris, Paris, France.
Yann HamonLaser Core Paris, Paris, France.
Yves CottinDepartement de Cardiologie, Centre Hospitalo-Universitaire de Dijon, Dijon, France.
Elie SerranoORL Et Chirurgie Cervico-Faciale, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France.
Lucien AbenhaimThe PGRx Study Group, London, UK.
Emmanuel TouzéNormandie Université, Université Caen Normandie, CHU Caen Normandie, Inserm U1237, Caen, France.
Centre Ophtalmologique d'Imagerie et de Laser · FRCentre Hospitalier Universitaire de Toulouse · FRCentre Hospitalier Universitaire Dijon Bourgogne · FRFHU Neurovasc · FRInserm · FRLondon School of Hygiene & Tropical Medicine · GBNormandie Université · FRUniversité de Bordeaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacovigilance reports of cerebral and cardiovascular events in those who use decongestants have triggered alerts related to their use. We aimed to assess the risk of stroke and myocardial infarction (MI) associated with the use of decongestants. We conducted a nested case-crossover study of patients with incident stroke and MI identified in France between 2013 and 2016 in two systematic disease registries. Decongestant use in the three weeks preceding the event was assessed using a structured telephone interview. Conditional logistic multivariable models were used to estimate the odds of incident MI and stroke, also accounting for transient risk factors and comparing week 1 (index at-risk time window, immediately preceding the event) to week 3 (reference). Time-invariant risk factors were controlled by design. In total, 1394 patients with MI and 1403 patients with stroke, mainly 70 years old or younger, were interviewed, including 3.2% who used decongestants during the three weeks prior to the event (1.0% definite exposure in the index at-risk time window, 1.1% in the referent time window; adjusted odds ratio (aOR), 0.78; 95%CI, 0.43-1.42). Secondary analysis yielded similar results for individual events (MI/stroke). We observed no increased risk of MI or stroke for patients 70 years of age and younger without previous MI or stroke who used decongestants.

Indexed as

AgedCase-Control StudiesCross-Over StudiesFemaleFranceHumansLogistic ModelsMaleMiddle AgedMyocardial InfarctionNasal DecongestantsOdds RatioRisk FactorsStrokeTime FactorsNasal Decongestants

Identifiers

PMID33603081
PMCPMC7893034
OpenAlexW3131233055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.